Optimal treatment with telaprevir for chronic HCV infection

Liver International

Volumn 33, Issue SUPPL. 1, 2013, Pages 3-13

  Jesudian, Arun B ^a   Jacobson, Ira M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Direct acting antivirals; Hepatitis C virus; Telaprevir

Indexed keywords

ANTIANEMIC AGENT; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE; ERYTHROPOIETIN; HEMOGLOBIN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; TELAPREVIR; TENOFOVIR;

ANEMIA; ANTIVIRAL ACTIVITY; BLOOD TRANSFUSION; COMBINATION CHEMOTHERAPY; DEPRESSION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECZEMA; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRESCRIPTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETREATMENT; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MUTATION;

EID: 84872022455     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12079     Document Type: Review

References (30)

1. Dienstag JL, McHutchison JG, et al. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-64.
2. World Health Organization. Hepatitis C. World Health Organization, Geneva, Switzerland 2000 October. Available at http:www.who.int/mediacentre/factsheets/fs165/en. Accessed: August 15, 2012.
3. El-Serag HB, Mason AC, et al. Rising incidence of heaptocellular carcinoma in the United States. New Eng J Med 1999; 340: 745-50.
4. Kim WR. The burden of Hepatitis C in the United States. Hepatology 2002; 36(Suppl): S30-4.
5. Ghany MG, Strader DB, Thomas DL, et al. AASLD Practice Guidelines: diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-75.
6. Jacobson IM. Treatment options for patients with chronic hepatitis C not responding to antiviral therapy. Clin Gastroenterol Hepatol 2009; 7: 921-30.
7. Lohmann V, Körner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-3.
8. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-6.
9. Pawlotsky JM. The hepatitis C viral life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132: 1979-98.
10. Reesink HW. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997-1002.
11. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis c virus replication in patients. Hepatology 2007; 46: 631-9.
12. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46: 640-7.
13. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008; 49: 163-9.
14. McHutchinson JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New Eng J Med 2009; 360: 1827-38.
15. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New Eng J Med 2009; 360: 1839-50.
16. McHutchinson JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. New Eng J Med 2010; 14: 1292-303.
17. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New Eng J Med 2011; 364: 2405-16.
18. Kieffer TL, Bartels G, Sullivan J., et al. Clinical Virology Results from Telaprevir Phase 3 Study ADVANCE. Hepatology 2010; 52(Suppl.): 223A.
19. Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. Hepatology 2010; 52(Suppl.): 401A.
20. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. New Eng J Med 2011; 364: 2417-28.
21. Foster GR, Zeuzem S, Andreone P, et al. Subanalyses of the telaprevir lead-in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorization. J Hepatol 2011; 54(Suppl. 1): S3-4.
22. Zeuzem S, Sulkowski MS, Zoulim F, et al. Long-term Follow-up of Patients with Chronic Hepatitis C Treated with Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin: Interim Analysis of the EXTEND Study. 61st Annual Meeting of the American Association for the Study of Liver Diseases. Hepatology 2010; 52(Suppl.): 436A.
23. Muir AJ, Poordad FF, McHutchison JG, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology 2011; 54: 1538-46.
24. Sulkowski MS, Roberts S, Afdhal NH, et al. Ribavirin dose modification in treatment-naïve and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies. J Hepatol 2012; 56(Suppl.): S459-60.
25. Hezode C, Dorival C, Zoulim F, Poynard T, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic nonresponders. First results of the French early access program (ANRS CO20-CUPIC). J Hepatol 2012; 56(Suppl.): S4.
26. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-68.
27. Dieterich D, Soriano V, Sherman K, et al. Telaprevir in combination with pegylated interferon-alfa-2a 1 ribavirin in HCV/HIV-coinfected patients: a 24-week treatment interim analysis. Presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012). 2012. Available at http://retroconference.org/2012b/Abstracts/42969.htm.
28. Foster GR, Hézode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 881-9.
29. Incivek (package insert). Cambridge, Mass: Vertex Pharmaceuticals, 2011. Available at http://www.incivek.com/. Accessed November 12, 2012.
30. Jacobson IM, Bartels DJ, Gritz L, et al. Futility rules in telaprevir combination treatment. J Hepatol 2012; 56(Suppl.): S24.